Elvitegravir/Cobicistat/Emtricitabine/Tenofovir (Stribild)

Overview | News | Research

Overview

Prescribing Information for Elvitegravir/Cobicistat/Emtricitabine/Tenofovir (Stribild) (PDF) (August 2012)
From Gilead Sciences, Inc.

News

EU Adopts Positive Opinion for Decision on Regulatory Approval of Quad (March/April 2013)
To read PDF, click here.
In HIV Treatment Bulletin, from HIV i-Base
AIDS Healthcare Foundation Challenges Gilead Over AIDS Drug Price Gouging of U.S. Government Programs on Stribild (February 1, 2013)
In CDC HIV/Hepatitis/STD/TB Prevention News Update, from U.S. Centers for Disease Control and Prevention
Stribild (the Quad) Approved in Canada (November 28, 2012)
From Canadian AIDS Treatment Information Exchange
FDA Approves Quad in U.S.: Price May Prohibit UK Access (September/October 2012)
To read PDF, click here.
In HIV Treatment Bulletin, from HIV i-Base
Stribild ("Quad") Recommended as Alternative First-Line HIV Treatment Regimen by U.S. Guidelines Panel (September 18, 2012)
From TheBody.com
ADAP Crisis Task Force and Gilead Sciences Agree on Stribild Pricing for ADAPs (September 10, 2012)
In Positively Aware, from Test Positive Aware Network
Stribild Included in Co-Pay and Assistance Programs (September 10, 2012)
In Positively Aware, from Test Positive Aware Network
Thoughts on "Quad" Approval by FDA (August 28, 2012)
From Journal Watch
Food and Drug Administration Approves Once-a-Day Pill for HIV (August 28, 2012)
In CDC HIV/Hepatitis/STD/TB Prevention News Update, from U.S. Centers for Disease Control and Prevention
Stribild (a.k.a. "Quad") Approved by FDA for First-Line Use; Becomes Third Single-Pill Regimen (August 27, 2012)
From U.S. Food and Drug Administration

VIEW ALL ARTICLES

Research

Updated Results on Quad: 96-Week Data From Phase 3 Studies (November/December 2012)
To read PDF, click here.
In HIV Treatment Bulletin, from HIV i-Base
Top 10 HIV Clinical Developments of 2012 (December 2012)
In HIV JournalView, from TheBodyPRO.com
Dolutegravir and the 88 Percent Rule (October 28, 2012)
From Journal Watch
Study Summaries From ICAAC 2012 (September/October 2012)
To read PDF, click here.
In HIV Treatment Bulletin, from HIV i-Base
Stribild (a.k.a. "Quad") Performs Well for People Over 50, Study Finds (September 23, 2012)
In The 52nd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC 2012), from TheBodyPRO.com
Stribild (a.k.a. "Quad") May Slightly Outperform Other Popular First-Line Options, Study Finds (September 15, 2012)
In The 52nd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC 2012), from TheBodyPRO.com
Integrated Analysis Shows "Quad" Pill Has Potent Activity With Fewer Side Effects (September 12, 2012)
From aidsmap.com
Stribild "Quad" Pill Has Potent Anti-HIV Activity With Fewer Side Effects (September 11, 2012)
From HIVandHepatitis.com
Studies Find Once-Daily "Quad" Is Safe and Effective (September/October 2012)
To read PDF, click here.
In Positively Aware, from Test Positive Aware Network
Quad Matches Atripla and Atazanavir Regardless of Viral Load or CD4 Count (August 17, 2012)
From HIVandHepatitis.com

VIEW ALL ARTICLES

MOST VIEWED ARTICLES

	HIV Management Today: Mental Health & HIV, the Uncharted Territory
	Danish Study Targets HIV Reservoir, in Latest Search for HIV Cure
	10 Top Studies Whose Impact Will Last Well Beyond CROI 2013
	CROI 2013: Women's Issues in HIV Research (Video)
	HIV Opportunistic Infection Guidelines Updated
	PrEP Failures and Successes: One Study Whose Impact Will Last Well Beyond CROI 2013

More Most Viewed Articles

TheBodyPRO.com is a service of Remedy Health Media, LLC, 500 5th Avenue, 19th Floor, New York, NY 10110. TheBodyPRO.com and its logos are trademarks of Remedy Health Media, LLC, and its subsidiaries, which owns the copyright of TheBodyPRO.com's homepage, topic pages, page designs and HTML code. General Disclaimer: TheBodyPRO.com is designed for educational purposes only and is not engaged in rendering medical advice or professional services. The information provided through TheBodyPRO.com should not be used for diagnosing or treating a health problem or a disease. It is not a substitute for professional care. If you have or suspect you may have a health problem, consult your health care provider.